DURHAM, N.C.--(BUSINESS WIRE)--Inspire Pharmaceuticals, Inc. (NASDAQ: ISPH) announced today that it received a Wells Notice letter on October 19, 2006 from the staff of the U.S. Securities and Exchange Commission (Commission), issued in connection with a Commission investigation that the Company previously disclosed relating to its Phase 3 clinical trial of the Company’s dry eye product candidate, Prolacria™. The Company’s Chief Executive Officer and its Executive Vice President, Operations and Communications, also received Wells Notices.
